Financing channel feed – Endpoints News

Financing channel feed

Exclusive: Ultragenyx secures first funds for Alzheimer's gene therapy spinout

9 months ago

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

9 months ago

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits

9 months ago

Rare disease biotech raises $47M Series C, plans for Phase 2 trial

9 months ago

As Amgen pursues GIP antagonism, a Novo Holdings-backed biotech does the same, boosting its Series A

9 months ago

RNA editing startup AIRNA raises $60M for clinical trial in rare liver disease

9 months ago

Exclusive: Startup aims to tackle ‘undruggable’ neuro targets with tech from Kevan Shokat's UCSF lab

9 months ago

In a tough market, private biotechs pursue IPOs and buyouts at the same time

10 months ago

Chinese biotech developing semaglutide biosimilar files for Hong Kong IPO

10 months ago

With new mission in psychiatry, Autobahn raises $100M to help back Phase 2 work

10 months ago

Exclusive: RA Capital invests $35M in UK cancer biotech CellCentric

10 months ago

Neurology startup from OrbiMed collab nabs $65M in Series A

10 months ago

At Third Arc Bio, former J&J leaders raise $165M to test oncology, autoimmune biologics

10 months ago

Flagship launches AI-powered biologics biotech with $50M backing

10 months ago

OrbiMed forms biotech with assets from China-based Keymed, enlists former Biohaven exec as CEO

10 months ago

George Church spinout raises $60M for protein therapies from genomically recoded organisms

10 months ago

Artiva's IPO raises $167M to fund company's autoimmune and cancer cell therapies

10 months ago

Parker Institute for Cancer Immunotherapy invests another $125M into research

10 months ago

Exclusive: TMRW Life Sciences raises $28M Series D to upgrade storage for egg freezing

10 months ago

Thyme Care scores $480M valuation in new funding round

10 months ago

AI drug development company gets $80M backing from Pfizer, Nvidia and Thermo Fisher

10 months ago

Three months after delisting, NGM Bio is back with $122M for slimmed-down pipeline

10 months ago

Investment firm launches with $100M for bioprocessing entrepreneurs

10 months ago

Renalys raises $37.8M to take Travere's kidney disease drug into Phase 3 trial in Japan

10 months ago

First page Previous page 10 11 121314 15 16 Next page Last page